| Company Name: |
Cool Pharm, Ltd |
| Tel: |
021-60455363 18019463053 |
| Email: |
sales@coolpharm.com |
|
| | N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide Basic information |
| Product Name: | N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide | | Synonyms: | BenzeneacetaMide,α-Methyl-4-(2-Methylpropyl)-N-(Methylsulfonyl)-;2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide;2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide;Reparixin racemate;α-Methyl-4-(2-methylpropyl)-N-(methylsulfonyl)benzeneacetamide;(Rac)-Reparixin;Reparixin Impurity 1;N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide | | CAS: | 957407-64-6 | | MF: | C14H21NO3S | | MW: | 283.39 | | EINECS: | | | Product Categories: | | | Mol File: | 957407-64-6.mol | ![N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide Structure](CAS/20150408/GIF/957407-64-6.gif) |
| | N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide Chemical Properties |
| density | 1.137±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Storage temp. 2-8°C | | pka | 5.161±0.23(predicted) | | form | Solid | | color | White to off-white |
| | N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide Usage And Synthesis |
| Uses | (Rac)-Reparixin is the isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively. | | References | [1] Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo). 2013;68(3):391-4. DOI:10.6061/clinics/2013(03)oa17
[2] Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. DOI:10.1073/pnas.0402090101
[3] Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75(4):721-9. DOI:10.1136/annrheumdis-2015-208093
[4] Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201(2):814-820. DOI:10.4049/jimmunol.1700755
[5] Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002. DOI:10.1021/jm061469t
[6] Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54. DOI:10.1111/j.1476-5381.2011.01566.x
[7] Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7. DOI:10.1248/bpb.34.120 |
| | N-[2-(4-Isobutyl-phenyl)-propionyl]-methane sulfonamide Preparation Products And Raw materials |
|